Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study

PURPOSE: After progression to immunotherapy, the standard of care for non-small cell lung cancer (NSCLC) was limited. Administration of the same or different immune checkpoint inhibitors (i.e., ICI rechallenge) may serve as a novel option. The present study aimed to evaluate the efficacy of ICI rech...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Ziyi, Hao, Xuezhi, Yang, Ke, Wang, Qi, Wang, Jing, Lin, Lin, Teng, Fei, Li, Junling, Xing, Puyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508034/
https://www.ncbi.nlm.nih.gov/pubmed/34982222
http://dx.doi.org/10.1007/s00432-021-03901-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508034/
https://www.ncbi.nlm.nih.gov/pubmed/34982222
http://dx.doi.org/10.1007/s00432-021-03901-2

Ejemplares similares